Lifesci Capital Has Bearish Estimate for VERA Q3 Earnings

Key Points

• Lifesci Capital has revised its Q3 2025 earnings estimates for Vera Therapeutics down to ($1.20) per share, significantly lower than the previous estimate of ($0.83).
• Vera Therapeutics reported earnings of ($1.20) per share for Q3, missing the consensus estimate of ($0.82) by ($0.38), emphasizing ongoing financial challenges for the company.
• Despite recent challenges, Vera Therapeutics has a majority of analysts rating it a "Moderate Buy" with an average target price of $63.00.

Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Investment analysts at Lifesci Capital dropped their Q3 2025 earnings per share (EPS) estimates for shares of Vera Therapeutics in a research note issued to investors on Tuesday, August 5th. Lifesci Capital analyst R. Katkhuda now expects that the company will post earnings per share of ($1.20) for the quarter, down from their prior estimate of ($0.83). The consensus estimate for Vera Therapeutics' current full-year earnings is ($2.89) per share. Lifesci Capital also issued estimates for Vera Therapeutics' Q4 2025 earnings at ($1.22) EPS and FY2025 earnings at ($4.44) EPS.

Several other research firms also recently weighed in on VERA. Cantor Fitzgerald dropped their target price on Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. Wolfe Research reaffirmed a "peer perform" rating on shares of Vera Therapeutics in a research report on Monday, August 4th. Scotiabank reaffirmed an "outperform" rating on shares of Vera Therapeutics in a research report on Tuesday, June 3rd. Guggenheim reiterated a "buy" rating on shares of Vera Therapeutics in a research note on Tuesday, June 3rd. Finally, JPMorgan Chase & Co. decreased their price objective on Vera Therapeutics from $56.00 to $53.00 and set an "overweight" rating for the company in a research note on Thursday, August 7th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Vera Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $63.00.

Vera Therapeutics Trading Up 2.1%

NASDAQ VERA traded up $0.42 during trading on Friday, hitting $20.59. The stock had a trading volume of 807,447 shares, compared to its average volume of 1,287,098. The company has a market capitalization of $1.31 billion, a PE ratio of -5.74 and a beta of 1.17. The company has a quick ratio of 17.03, a current ratio of 17.03 and a debt-to-equity ratio of 0.16. The firm has a 50 day moving average price of $22.74 and a 200 day moving average price of $24.92. Vera Therapeutics has a twelve month low of $18.53 and a twelve month high of $51.61.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.38). During the same period in the previous year, the business earned ($0.62) earnings per share.

Insiders Place Their Bets

In related news, Director Patrick G. Enright bought 40,607 shares of the company's stock in a transaction dated Tuesday, June 24th. The shares were acquired at an average price of $22.35 per share, with a total value of $907,566.45. Following the completion of the acquisition, the director owned 3,596,593 shares in the company, valued at approximately $80,383,853.55. This trade represents a 1.14% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 16.30% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of VERA. Vestal Point Capital LP increased its holdings in shares of Vera Therapeutics by 132.6% in the first quarter. Vestal Point Capital LP now owns 2,500,000 shares of the company's stock valued at $60,050,000 after purchasing an additional 1,425,000 shares during the period. Avoro Capital Advisors LLC increased its holdings in shares of Vera Therapeutics by 30.2% in the fourth quarter. Avoro Capital Advisors LLC now owns 5,610,000 shares of the company's stock valued at $237,247,000 after purchasing an additional 1,300,410 shares during the period. Lord Abbett & CO. LLC increased its holdings in shares of Vera Therapeutics by 170.8% in the fourth quarter. Lord Abbett & CO. LLC now owns 1,153,670 shares of the company's stock valued at $48,788,000 after purchasing an additional 727,656 shares during the period. Integral Health Asset Management LLC increased its holdings in shares of Vera Therapeutics by 130.0% in the fourth quarter. Integral Health Asset Management LLC now owns 1,150,000 shares of the company's stock valued at $48,634,000 after purchasing an additional 650,000 shares during the period. Finally, Voya Investment Management LLC grew its holdings in Vera Therapeutics by 572.2% during the fourth quarter. Voya Investment Management LLC now owns 695,091 shares of the company's stock worth $29,395,000 after acquiring an additional 591,682 shares during the period. Institutional investors and hedge funds own 99.21% of the company's stock.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.